BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37781631)

  • 1. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
    Flynn PA; Long MD; Kosaka Y; Mulkey JS; Coy JL; Agarwal A; Lind EF
    bioRxiv; 2023 Sep; ():. PubMed ID: 37781631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
    Flynn PA; Long MD; Kosaka Y; Long N; Mulkey JS; Coy JL; Agarwal A; Lind EF
    Front Immunol; 2024; 15():1297338. PubMed ID: 38495876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication.
    Rickmann M; Krauter J; Stamer K; Heuser M; Salguero G; Mischak-Weissinger E; Ganser A; Stripecke R
    Ann Hematol; 2011 Sep; 90(9):1047-58. PubMed ID: 21520003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses.
    Lau CM; Nish SA; Yogev N; Waisman A; Reiner SL; Reizis B
    J Exp Med; 2016 Mar; 213(3):415-31. PubMed ID: 26903243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive Flt3 signaling impacts conventional dendritic cell function.
    Wilson KR; Macri C; Villadangos JA; Mintern JD
    Immunol Cell Biol; 2024 May; ():. PubMed ID: 38693626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
    Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
    Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.
    Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of NK cell RIPK1 with Prognosis of Acute Myeloid Leukemia Patients with FLT3-ITD Mutation].
    Yu G; Chen JG; Tan JS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1480-1485. PubMed ID: 33067941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
    Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
    Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
    Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
    Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia.
    Rickmann M; Macke L; Sundarasetty BS; Stamer K; Figueiredo C; Blasczyk R; Heuser M; Krauter J; Ganser A; Stripecke R
    Ann Hematol; 2013 Aug; 92(8):1079-90. PubMed ID: 23616009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
    Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
    He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
    Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.
    He BL; Yang N; Man CH; Ng NK; Cher CY; Leung HC; Kan LL; Cheng BY; Lam SS; Wang ML; Zhang CX; Kwok H; Cheng G; Sharma R; Ma AC; So CW; Kwong YL; Leung AY
    EMBO Mol Med; 2020 Apr; 12(4):e10895. PubMed ID: 32134197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
    Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
    Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.